Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Breast Neoplasms

Breast Neoplasms

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Breast Neoplasms

105 trials tracked for Breast Neoplasms: 27 in phase 3 or 4 and 10 with published results. The most-cited published study has 2786 citations.

105Trials tracked
27Phase 3 & 4
0Recruiting
10With published results
Phase distribution
Phase 4 3 Phase 3 24 Phase 2 48 Phase 1 11 Other / NA 19
  1. Phase 3 Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer Completed · 2,786 cited
  2. Phase 3 A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Completed · 2,190 cited
  3. Phase 3 A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Completed · 544 cited
  4. Phase 3 Regional Anesthesia and Breast Cancer Recurrence Completed · 415 cited
  5. Phase 3 Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment Completed · 211 cited
  6. Phase 3 A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) Completed · 190 cited
Show 44 more trials
  1. Phase 3 A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer Completed · 117 cited
  2. Phase 3 A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4] Completed · 80 cited
  3. Phase 3 A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Completed · 47 cited
  4. Phase 3 Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta® Completed · 38 cited
  5. Phase 4 Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer Completed
  6. Phase 4 Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China Completed
  7. Phase 4 A Study of Abemaciclib in Indian Women With Advanced Breast Cancer Completed
  8. Phase 3 Study Assessing The Interest of Indocyanine Green Fluorescence Imaging With Radioisotope Method For Sentinel Lymph Node Biopsy in Patients With Breast Cancer Completed
  9. Phase 3 Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer Completed
  10. Phase 3 Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03 Completed
  11. Phase 3 Pain Control for Breast Cancer Patients Receiving Injection of Radioactive Tracer Completed
  12. Phase 3 Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer Completed
  13. Phase 3 Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer Completed
  14. Phase 3 A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer Completed
  15. Phase 3 Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy Completed
  16. Phase 3 Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer Completed
  17. Phase 3 Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane Completed
  18. Phase 3 A Phase III Trial For Patients With Metastatic Breast Cancer Completed
  19. Phase 3 LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment Completed
  20. Phase 3 Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer Completed
  21. Phase 3 A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer Completed
  22. Phase 2 Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms Completed
  23. Phase 2 Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy Completed
  24. Phase 2 Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer Completed
  25. Phase 2 A Study of E7389 in Advanced/Metastatic Breast Cancer Patients Completed
  26. Phase 2 Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer Completed
  27. Phase 2 Neoadjuvant Tamoxifen in Locally Advanced Breast Cancer in a Low/Middle Income Country Completed
  28. Phase 2 BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer Completed
  29. Phase 2 Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer Completed
  30. Phase 2 A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer Completed
  31. Phase 2 Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT) Completed
  32. Phase 2 Vaccination of High Risk Breast Cancer Patients Completed
  33. Phase 2 Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer Completed
  34. Phase 2 Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer Completed
  35. Phase 2 Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer Completed
  36. Phase 2 A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer Completed
  37. Phase 2 BAY43-9006 - Phase II in Advanced Breast Cancer Completed
  38. Phase 2 Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer Completed
  39. Phase 2 A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) Completed
  40. Phase 2 Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer Completed
  41. Phase 2 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab Completed
  42. Phase 2 A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors Completed
  43. Phase 2 Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases Completed
  44. Phase 2 Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer Completed

Showing the 50 most-cited and recently-updated of 105 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Breast Neoplasms: what the trials found

Several trials evaluated systemic therapies for breast cancer, showing significant improvements in progression-free survival (PFS) and objective response rates. Specifically, PD-0332991 demonstrated a statistically significant improvement in PFS (p<0.000001) and higher objective response rates compared to the control 9. Similarly, talazoparib showed superior PFS (p<0.0001) and significantly higher objective response rates (62.6% vs 27.2%, p<0.0001) 5. Palbociclib also demonstrated a significant improvement in PFS based on investigator assessment (p=0.0012), though this did not reach statistical significance via blinded independent central review 11.

In the context of HER2-positive advanced or metastatic breast cancer, Lapatinib was associated with significantly improved progression-free survival (p=0.019) and a higher median PFS in the HER2-positive population (35.4 vs 13.0; p=0.019) 21. Regarding surgical outcomes and pain management, general anesthesia and opioids did not show significant differences in recurrence rates or post-surgical/neuropathic pain levels compared to other protocols 7. Additionally, the use of a lidocaine patch was associated with low median post-procedural pain scores and favorable sensory/affective pain scores 14.

Other findings include the impact of hormonal and bone-related treatments. Tamoxifen showed a statistically significant improvement in disease-free survival at 36 months (p=0.00003) but did not significantly impact overall survival (p=0.15737); it was also associated with significant changes in bone mineral density 19. Zoledronic acid was evaluated for its effects on lumbar spine and total hip bone mineral density 20. Regarding chemotherapy support, LA-EP2006 showed a trend toward shorter mean duration of severe neutropenia (p=0.05) during cycle 1 13. Carboplatin was associated with higher rates of total pathological complete response (p=0.0126) and increased rates of breast-conserving surgery (p=0.0228), though it did not significantly impact overall survival 6.

For the clinician treating this condition

  • PD-0332991, talazoparib, and Palbociclib are associated with statistically significant improvements in progression-free survival (PFS) compared to respective controls.
  • Lapatinib shows a significant benefit in progression-free survival for patients with HER2-positive advanced or metastatic breast cancer.
  • Standard interventions like general anesthesia/opioids and lidocaine patches were evaluated for pain management, with the latter showing low post-procedural scores.

AI synthesis of 10 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Phenotype-guided pharmacologic management of postoperative sleep disturbance in breast cancer patients may improve outcomes
Drug Pipeline Sys. Review
Phenotype-guided pharmacologic management of postoperative sleep disturbance in breast cancer patients may improve outcomes Tailored Medication Options for Sleep Issues After Breast Surgery
This narrative review explores the pharmacological management of postoperative sleep disturbance (PSD) in breast cancer patients following s…
Newer strategies suggest matching specific medications to the type of sleep issues patients face after breast cancer surgery.
Frontiers Aug 24, 2026
Perioperative esketamine significantly reduces postoperative depressive symptom scores and short-term pain in breast cancer surgery
Drug Pipeline Meta-analysis
Perioperative esketamine significantly reduces postoperative depressive symptom scores and short-term pain in breast cancer surgery Esketamine may lower depression scores after breast cancer surgery
This meta-analysis of 1,515 patients found that perioperative esketamine significantly reduced postoperative depressive symptom scores at da…
New data suggests esketamine could help manage feelings of depression and some pain for patients undergoing breast cancer surgery.
Frontiers Aug 23, 2026
Acupuncture reduces Pittsburgh Sleep Quality Index scores in patients with breast cancer-related insomnia
Oncology Meta-analysis
Acupuncture reduces Pittsburgh Sleep Quality Index scores in patients with breast cancer-related insomnia Acupuncture may improve sleep quality for breast cancer patients
This meta-analysis of 2025 patients with breast cancer-related insomnia found that acupuncture significantly reduced Pittsburgh Sleep Qualit…
New data suggests acupuncture can help improve sleep quality for those dealing with insomnia related to breast cancer treatment.
Jul 1, 2026
Perioperative nursing training protocol improves satisfaction in implant-based breast reconstruction
Oncology Sys. Review
Perioperative nursing training protocol improves satisfaction in implant-based breast reconstruction Specialized Nursing Training Improves Satisfaction in Breast Reconstruction Patients
This quasi-experimental study of 82 patients undergoing implant-based breast reconstruction found that a perioperative nursing protocol supp…
A new nursing training program may improve patient satisfaction with surgical outcomes and care during breast reconstruction.
Frontiers Jun 19, 2026